Eine Studie zu subkutanem Emicizumab bei Kindern mit Hämophilie A und Faktor-VIII-Hemmkörpern (FVIII)

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

  • Hämophilie
  • Hämophilie A
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Stadt
  • Bonn
Studien-ID:

NCT02795767 2016-000073-21 HAVEN2 BH29992

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02795767, BH29992, 2016-000073-21, HAVEN2 Studien-ID
      Emicizumab Treatments
      Hemophilia A Condition
      Official Title

      A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors

      Einschlusskriterien

      All Gender
      ≤ 17 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Children less than (<) 12 years of age, with allowance for participants 12 to 17 years of age who weigh <40 kilograms (kg) (Cohort A only); and participants <2 years of age will be allowed to participate only after the protocol-defined interim data review criteria are met (Cohort A only)
      • Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is [i.e.], greater than or equal to [>/=] 5 bethesda units [BU])
      • Requires treatment with bypassing agents
      • Adequate hematologic, hepatic, and renal function
      Exclusion Criteria
      • Inherited or acquired bleeding disorder other than hemophilia A
      • Ongoing (or planning to receive during the study) immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII
      • Previous (in the past 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease
      • Other disease that may increase risk of bleeding or thrombosis
      • History of clinically significant hypersensitivity associated with monoclonal antibody therapy or components of the emicizumab injection
      • Known infection with human immunodeficiency virus (HIV) or hepatitis B or C virus
      • Use of systemic immunomodulators at enrollment or planned use during the study period
      • Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
      • Inability (or unwillingness by caregiver) to receive (allow receipt of) blood or blood products (or any standard-of-care treatment for a life-threatening condition)
      • Participants who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA), in the investigator's judgement

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr